BioAtla Inc.

BCAB | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.74

+$0.42 (+31.82%)

At close: Aug 28, 2026, 4:00 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+31.82%

(1D)

Rating

Updated: Aug 5, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $2.88M

1D Range

1.58 2.06

52W Range

1.07 71.50

Valuation (TTM)

PE -0.07

PB -0.08

EV/EBITDA -0.25

Valuation (NTM)

Forward PE N/A

Forward PEG -0.00

Price Target $250

Cash Flow

FCF Yield -815.5%

SBC Adj. FCF Yield -954.0%

SBC Impact -17.0%

Margins

Gross Margin -4.2%

Operating Margin -1581.3%

FCF Margin -1174.1%

Growth (CAGR)

Revenue 3Y | 5Y 23.1% | 38.0%

Dil EPS 3Y | 5Y 66.2% | 33.0%

FCF 3Y | 5Y 68.7% | 20.9%

Returns

ROA -330.9%

ROE 89.3%

ROIC 318.0%

Financial Health

Net Debt

$4.32M

Current Ratio 0.20

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cance...

Sector Healthcare

Industry Biotechnology

Employees 41

IPO Date Dec 15, 2020

Website www.bioatla.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 12, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞